160 related articles for article (PubMed ID: 33752752)
1. Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY): a multi-center randomized controlled study comparing alternative antibiotic regimens in patients undergoing tumor resections with endoprosthetic replacements-a statistical analysis plan.
Schneider P; Heels-Ansdell D; Thabane L; Ghert M;
Trials; 2021 Mar; 22(1):223. PubMed ID: 33752752
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.
; Ghert M; Schneider P; Guyatt G; Thabane L; Vélez R; O'Shea T; Randall RL; Turcotte R; Wilson D; Wunder JS; Baptista AM; Cheng EY; Doung YC; Ferguson PC; Giglio V; Hayden J; Heels-Ansdell D; Khan SA; Sampath Kumar V; McKay P; Miller B; van de Sande M; Zumárraga JP; Bhandari M
JAMA Oncol; 2022 Mar; 8(3):345-353. PubMed ID: 34989778
[TBL] [Abstract][Full Text] [Related]
3. Surgical Duration Is Independently Associated with an Increased Risk of Surgical Site Infection and May Not Be Mitigated by Prolonged Antibiotics: A Secondary Analysis of the PARITY Trial of Infection After Lower-Extremity Endoprosthetic Reconstruction for Bone Tumors.
Zeitlinger L; Wilson M; Randall RL; Thorpe S;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):79-86. PubMed ID: 37466584
[TBL] [Abstract][Full Text] [Related]
4. Operative Treatment and Outcomes of Pediatric Patients with an Extremity Bone Tumor: A Secondary Analysis of the PARITY Trial Data.
Bozzo A; Yeung CM; Van De Sande M; Ghert M; Healey JH;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):65-72. PubMed ID: 37466582
[TBL] [Abstract][Full Text] [Related]
5. Patient and Surgical Risk Factors for Surgical Site Infection in Lower-Extremity Oncological Endoprosthetic Reconstruction: A Secondary Analysis of the PARITY Trial Data.
Slawaska-Eng D; Gazendam AM; Kendal J; Schneider P; Becker RG; Freitas JP; Bernthal N; Ghert M;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):41-48. PubMed ID: 37466579
[TBL] [Abstract][Full Text] [Related]
6. Surgical Site Infection Is Not Associated with 1-Year Progression-Free Survival After Endoprosthetic Reconstruction for Lower-Extremity Osteosarcoma: A Secondary Analysis of PARITY Study Data.
Jackson KJ; Sullivan CD; Zimel MN; Wustrack RL;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):49-56. PubMed ID: 37466580
[TBL] [Abstract][Full Text] [Related]
7. Surgical Site Infection in Patients Managed with an Endoprosthesis for the Treatment of Cancer: Evaluation of Patient, Disease, and Index Surgical Factors.
Ray GS; Werth P; Alexander JH; Eward WC; Bernthal NM; Jeys LM; Funovics P; Windhager R; Temple HT; Lozano-Calderon S; Avedian RS; Jutte PC; Ghert M; Ruggieri P; Henderson ER;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):87-96. PubMed ID: 37466585
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study.
Ghert M; Deheshi B; Holt G; Randall RL; Ferguson P; Wunder J; Turcotte R; Werier J; Clarkson P; Damron T; Benevenia J; Anderson M; Gebhardt M; Isler M; Mottard S; Healey J; Evaniew N; Racano A; Sprague S; Swinton M; Bryant D; Thabane L; Guyatt G; Bhandari M;
BMJ Open; 2012; 2(6):. PubMed ID: 23194956
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic antibiotic regimens in tumor surgery (PARITY) survey.
Hasan K; Racano A; Deheshi B; Farrokhyar F; Wunder J; Ferguson P; Holt G; Schwartz H; Petrisor B; Bhandari M; Ghert M
BMC Musculoskelet Disord; 2012 Jun; 13():91. PubMed ID: 22676321
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Functional Recovery among Musculoskeletal Oncology Patients Undergoing Lower Extremity Endoprosthetic Reconstruction.
Gazendam AM; Schneider P; Heels-Ansdell D; Bhandari M; Busse JW; Ghert M
Curr Oncol; 2022 Oct; 29(10):7598-7606. PubMed ID: 36290877
[TBL] [Abstract][Full Text] [Related]
11. High infection rate outcomes in long-bone tumor surgery with endoprosthetic reconstruction in adults: a systematic review.
Racano A; Pazionis T; Farrokhyar F; Deheshi B; Ghert M
Clin Orthop Relat Res; 2013 Jun; 471(6):2017-27. PubMed ID: 23404421
[TBL] [Abstract][Full Text] [Related]
12. Central Adjudication Committee and Clinical Site Investigator Agreement on Outcomes in the PARITY Trial: A Secondary Analysis of the PARITY Trial Data.
Slawaska-Eng D; Giglio V; Gazendam AM; Schneider P; Bernthal N; Ghert M;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):73-78. PubMed ID: 37466583
[TBL] [Abstract][Full Text] [Related]
13. Proximal Tibia Reconstruction After Bone Tumor Resection: Are Survivorship and Outcomes of Endoprosthetic Replacement and Osteoarticular Allograft Similar?
Albergo JI; Gaston CL; Aponte-Tinao LA; Ayerza MA; Muscolo DL; Farfalli GL; Jeys LM; Carter SR; Tillman RM; Abudu AT; Grimer RJ
Clin Orthop Relat Res; 2017 Mar; 475(3):676-682. PubMed ID: 27103142
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for All-Cause Early Reoperation Following Tumor Resection and Endoprosthetic Reconstruction: A Secondary Analysis from the PARITY Trial.
Kendal JK; Slawaska-Eng D; Gazendam A; Schneider P; Wessel LE; Ghert M; Bernthal NM;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):4-9. PubMed ID: 37466573
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic antibiotic regimens in tumour surgery (PARITY): a pilot multicentre randomised controlled trial.
PARITY Investigators
Bone Joint Res; 2015 Sep; 4(9):154-62. PubMed ID: 26423584
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy and Endoprosthetic Reconstruction for Lower Extremity Sarcomas: Does Timing Impact Complication Rates?
Gazendam AM; Schneider P; Spiguel A; Ghert M
Ann Surg Oncol; 2022 Nov; 29(12):7312-7317. PubMed ID: 35864365
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Endoprosthetic reconstruction for large extremity soft-tissue sarcoma with juxta-articular bone involvement: functional and survival outcome.
Yan TQ; Zhou WH; Guo W; Yang RL; Dong S; Liang WM; Sun YF
J Surg Res; 2014 Mar; 187(1):142-9. PubMed ID: 24405612
[TBL] [Abstract][Full Text] [Related]
19. Endoprosthetic reconstruction for malignant bone and soft-tissue tumors.
Asavamongkolkul A; Waikakul S; Phimolsarnti R; Kiatisevi P; Wangsaturaka P
J Med Assoc Thai; 2007 Apr; 90(4):706-17. PubMed ID: 17487125
[TBL] [Abstract][Full Text] [Related]
20. Incidence of and Risk Factors for Thromboembolism After Endoprosthetic Reconstruction in Musculoskeletal Oncology Patients.
Sabharwal S; LiBrizzi CL; Forsberg JA; Morris CD; Levin AS;
J Bone Joint Surg Am; 2023 Jul; 105(Suppl 1):29-33. PubMed ID: 37466577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
